Navigation Links
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., , which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners, announced that Trine Pharmaceuticals, Inc. ("Trine") is presenting a poster detailing the results of a Phase 2a study conducted in 2006 for crofelemer for diarrhoea predominant irritable bowel syndrome (d-IBS) today at Digestive Disease Week in Washington, D.C. Trine licensed crofelemer for the d-IBS indication from Napo in June 2004. Trine has worldwide development and commercialization rights to crofelemer for d-IBS. The objective of the trial was to evaluate the safety and efficacy of crofelemer in men and women with d-IBS.

The trial was designed as a randomized double-blind placebo-controlled, dose-ranging (placebo, 125 mg, 250 mg, and 500 mg bid) study over a 12-week treatment period in 246 patients with d-IBS (Rome II criteria), including both males and females, whose average age was 50 years old.

IBS symptoms (pain, urgency, stool frequency and consistency, and adequate relief) were self-reported by the patients via an interactive voice response system (IVRS). Patients needed to exhibit active disease during the two-week baseline period as defined by a mean daily stool frequency greater than or equal to 2/day, pain score greater than or equal to 1 and stool consistency greater than or equal to 3 (5-point Lickert scale for pain and consistency) to be enrolled. Patients received treatment for 12 weeks followed by a two-week treatment free period.

Results: The 125 mg bid of crofelemer exhibited a consistent response during each month among most efficacy endpoints in women with d-IBS (see table) reaching statistical significance (p<0.05) for pain. Crofelemer had little effect on the stool consistency score, though there was a trend toward redu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/28/2015)...  With the heroin epidemic in the ... Jacksonville -based Lakeview Health drug and alcohol treatment ... explain why fentanyl is causing a new wave of ... more potent than pharmaceutical grade heroin and often illegally ... of death skyrockets. "Fentanyl can be an ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... "Cancer Biomarker Market by Tumor (Breast, Lung, Prostate) Type ... Immunoassay) Application (Diagnostic, Drug Discovery, Prognostic) & Geography - ... Biomarkers Market is expected to reach around 17,689.0 Million ... the forecast period of 2015 to 2020. ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... Digital Assent has expanded its leadership ... award-winning PatientPad® solution.  The PatientPad is a ... the patient intake process and deliver targeted health information ... added five key executives to its sales, business development, ...
... FRISCO, Texas, March 31, 2011 Assured Pharmacy (APHY: ... to more than 3,000 sufferers of chronic pain, announced ... the month of January  2011 were $1,430,278 which equates ... of 22.4 percent when compared with total sales per ...
Cached Medicine Technology:Digital Assent Expands Leadership Team to Address Rapidly Growing Demand for the PatientPad 2Digital Assent Expands Leadership Team to Address Rapidly Growing Demand for the PatientPad 3Assured Pharmacy Reports Same Store Sales for the Month of January 2011 2
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees ... and InHealth media is a global sales and communications firm that offers U.S. brands ... continue our business relationship with Mr. Reid Eckert, as his interpretation of the nutritional ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, ... the treatment of prostate cancer, has announced the roll-out of its newest technology ... center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at ...
(Date:8/29/2015)... Church, VA (PRWEB) , ... August 30, 2015 ... ... **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... much more than a simple digital handwritten signature. , Clinical trial ...
(Date:8/29/2015)... ... 29, 2015 , ... It can be uncomfortable to wear ... and sweat. "In order to prevent these problems, I conceived of my design," ... MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It improves comfort for ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... SAN FRANCISCO, April 17 The San Francisco Bay Area ... for the Cure Affiliates across the country to applaud the ... to L ife-saving E arly Detection, R ... Sens. Dianne Feinstein (D-CA), Edward Kennedy (D-MA) and Kay Bailey ...
... come from fertility clinic embryos that otherwise would be ... hoping to use U.S. funding for embryonic stem cell ... otherwise would be discarded, the National Institutes of Health ... controversial research -- such as using stem cells taken ...
... though suicide outranks homicide as a cause of death ... policymakers who want to create prevention strategies - especially ... study shows."The Institute of Medicine has documented that half ... a mental disorder, but death certificates register little of ...
... April 17 Not since the United States Great ... significant hardships to their health and well-being across the ... Losing jobs at a rapid pace, people are at ... identity, security and status. Yet Miami,s St. Thomas ...
... process the conversion of medical records from microfiche to digital form. ... ... Penny Imaging Exchange, Inc. (PIE) has acquired new technology from Germany ... the DRS Digitizer . With the Obama administration pushing to ...
... Alliance, Inc. (Nasdaq: SUAI ) ("SUA" ... Co., a leading independent proxy advisory firm, has recommended that ... for the nominees recommended by dissident stockholder Hallmark Financial Services, ... held at 9:00 a.m. local time on May 5, 2009 ...
Cached Medicine News:Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 2Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3
Mathews hand drill, with knurled shank and rotating head....
Hudson Downs hand drill....
Io is a surgical digital microscope with head mounted display HMD (Callisto)....
... the development of the minimally ... innovative solution that allows microsurgery ... less invasive. The olympus MINI ... surgical microscope, the neuroendoscope upgrade ...
Medicine Products: